The nod means the cobalt-chromium stent is "available in all of the major markets worldwide," according to a press releaase, including the U.S., Europe, China and India.
The drug-eluting stent is at the vanguard of a new breed of stents that are thinner and more visible under X-ray.
"Xience Prime leverages the best of Xience V, which is the market-leading drug eluting stent in Japan and throughout the world, and the introduction of Xience Prime further advances Abbott’s leadership position," Robert Hance, senior vice president, vascular, said in prepared remarks.
Arteriocyte wins FDA nod for IDE trial
Arteriocyte said it won investigational device exemption approval from the FDA for a Phase I clinical trial of its Magellan MAR01 technology in treating compartment syndrome. Read more